Dr Francesco Forconi

Haematology 04697789

  • Bupa Platinum consultant
  • Fee assured
  • Open Referral network
Bupa Platinum consultant
Fee assured
Open Referral network

Specialises in

  • Haemato-oncology


  • Face-to-face consultations
  • Video and telephone consultations

About me

Francesco Forconi (MD, DM, PhD, FRCPath) is a Professor of Haematology at the University of Southampton, UK and a Consultant Haematologist at the University of Southampton Hospital Trust.

His clinical activity is primarily dedicated to the care of patients with chronic lymphocytic leukaemia (CLL) and non-Hodgkin lymphomas. He leads the CLL Service and a broad portfolio of phase I/II/III interventional clinical trials and real-life observational studies as chief or principal investigations. He is dedicated to improving patient experience together with CLL advocacy groups including CLL Horizons, Leukaemia Care and CLL Support Association, and implementing large patients data managing platforms.

Prof. Forconi is the UK lead of the international CRUK ECRIN-M3 consortium in monoclonal B-cell lymphocytosis, investigating the early diagnosis of CLL and lymphomas in close partnerships with European and international stakeholders. He has been a Member of the UK NCRI Haematological Oncology Clinical Studies Group and continues to be an active participant in the UK NCRI CLL subgroup activities. He is also an active member of the UK CLL Forum Scientific Committee and more recently of the NCRI Lymphoma Science Study Group. He is an active core member of the International Hairy Cell Leukemia Foundation, USA and leads Southampton as a �Center of Excellence� for Hairy Cell Leukemia. He has contributed to the UK and International guidelines on the diagnosis and management of Hairy Cell Leukemia. He has served the National Institute for Clinical Excellence (NICE) for several technology appraisals for novel agents in clinical practice.

He has been Editorial Board Member for BLOOD and regularly contributes as a reviewer for the major journals of clinical and scientific immunology, oncology, and haematology; has chaired sessions at major international and national conferences including the American Society of Hematology (ASH) and the British Society of Haematology (BSH) annual meetings. He has given educational contributions at major national and international haemato-oncology conferences including those of the UK CLL Forum, the European Haematology Association, the American Society of Haematology, and the European Society of Medical Oncology (ECCO/ESMO).

Francesco is also the clinical scientific leader of the academic Cancer B-cell Group, at the Faculty of Medicine, University of Southampton, comprising world-class scientists investigating the pathogenesis and clinical behaviour of lymphomas and leukaemias. He holds grants with a focus on early cancer interception by analysis of the tumour B-cell receptor and on novel antibodies targeting its unique structures and functions. His most recent investigations have also expanded around the cancer-specific post-translation modifications (oligomannose-type glycans) of the B-cell receptor of lymphomas and how to target them therapeutically. He is currently the author of >170 peer-reviewed publications with >80% publications in the top 10% of scientific journals.

Areas of interest

leukaemia; lymphoma; chronic lymphocytic leukaemia; hairy cell leukaemia; low-grade lymphoma; marginal zone lymphoma; follicular lymphoma; monoclonal gammopathies; lymphoproliferative disorders; phase I/II/III clinical trials; antibody therapies; small molecule inhibitors.

Medical secretaries

My qualifications & training
Consultant's practices
Report this page Edit details Print page

The information contained on Finder is submitted by consultants, therapists and healthcare services, and is declared by these third parties to be correct and compliant with the standards and codes of conduct specified by their relevant regulatory body. Bupa cannot guarantee the accuracy of all of the information provided.

You can find out more about the information on Finder and our website terms of use.